Air Liquide recently announced that it has entered into exclusive negotiations with French private equity firm Hivest Capital Partners for the divestment of its subsidiary CRYOPDP.

One of the top leaders in its field, CRYOPDP aims to improve the health of people around the world by providing global innovative temperature-controlled logistics solutions to the Clinical Research and Cell & Gene Therapy Communities.

With headquarters in France, CRYOPDP has more than 250 employees in 12 countries and operates in more than 150 countries.

This decision illustrates Air Liquide’s strategy to regularly review its asset portfolio in order to focus on key businesses and geographies so as to maximize its performances.